Third Party Payors, including self insured health plans, may be entitled to compensation as a result of this litigation.
The lawsuit is about the price of Loestrin 24 Fe and Minastrin 24 Fe and whether the manufacturer of these drugs and generic manufacturers impaired or delayed the availability of allegedly less expensive generic versions. End-Payor Plaintiffs claim that class members were injured as a result of the challenged conduct by paying more for Loestrin 24 Fe, Minastrin 24 Fe, and their generic equivalents. Defendants deny all these allegations. End-Payor Plaintiffs have agreed to Settlements totaling $63,500,000 with the Defendants. The total settlement figure is comprised of settlements with two Defendants.
The first settlement with the Lupin Defendants (the “Lupin Settlement”), has resulted in a $1,000,000.00 settlement. After allocation to claimants of 30.03% of the costs, fees, and expenses incurred in connection with the Lupin Settlement and the litigation, there will not be sufficient funds to facilitate a claims process and distribution regarding this settlement. As a result, no claim can be accepted for pharmaceutical purchases/payments/reimbursements related to the Lupin Settlement and any residual funds may be dispersed to a charity approved by the Court.
The second settlement with the Warner Chilcott Defendants (the “Warner Chilcott Settlement”) has resulted in a $62,500,000 settlement. This settlement includes only a Third Party Payor Class ("TPP Class"), and you are generally included in the TPP Class if you are a TPP (such as a self-insured health plan) that purchased, paid, and/or provided reimbursement for some or all of the purchase price for Loestrin 24 Fe, Minastrin 24 Fe, and/or generic versions of these drugs, for consumption by your members, employees, insureds, participants, or beneficiaries, other than for resale, in the United States and its territories, from September 1, 2009 through and until September 17, 2019.